The corona virus has caused havoc all over the world. Experts say that until the corona vaccine is ready. Until then, it cannot be got rid of. Although no corona vaccine has yet received Emergency Use Authority in India, the central administration is in the final stages of preparing several vaccines.
A vaccine dry run will be conducted in Andhra Pradesh, Assam, Gujarat and Punjab from next week. The government has informed that the dry run will help in understanding whether there is any deficiency in the whole process. The government said, it will see end to end mobilization, Kovid vaccination process and usage of Co-WIN. “Co-WIN is a mobile application that will be monitored online through the entire process.
The dry run will be the same as the vaccine planned on the vaccine cause or the vaccine will be applied. Vaccine will not be given in this dry run, only people’s data will be taken, it will be uploaded on cowin app. Many things like micro planning, session site management and securing online data will be tested.
The ministry says that it will create rehearsal plans in two districts of every state, especially for five different vaccine centers – such as district hospital, community health center or primary health center, urban center, private hospital, rural outreach center. Ludhiana and Shaheed Bhagat Singh Nagar of Punjab have been selected for the dry run of Kovid Vaccination. Ludhiana Deputy Commissioner V. Sharma said that 805 service locations have been set for vaccination here.
So far, three forma companies in India have sought approval for emergency use of their vaccine. Pfizer was at the forefront of the vaccine race, on December 4, it first sought approval from the Indian government for emergency use of the vaccine. In India, the Oxford Vaccine with Serum Institute applied for the approval of the second emergency use. Hyderabad-based company Bharat Biotech, which is making the vaccine in collaboration with the Indian Council of Medical Research (ICMR), has also applied for emergency use of its vaccine.